FOXO4-DRI Dosing & Reconstitution Guide

The dosing protocol for FOXO4-DRI is primarily informed by preclinical studies conducted in mouse models. Administration is suggested via subcutaneous injection, although this is extrapolated from intraperitoneal (IP) injection methods used in rodents. Research indicates a treatment frequency of every three days over the course of three weeks, based on findings from these animal studies. Specifically, a dose of 5 mg/kg has been observed for IP administration, but it is crucial to note that no established dosing guidelines exist for human use. Consequently, any application in human research should consider this lack of established protocols and the inherent risks associated with extrapolating animal data to human subjects. The three-week cycle length reflects the duration used in the mouse protocols, further underscoring the need for caution in translating these findings to human applications.

Proper storage conditions for FOXO4-DRI are critical to maintaining the integrity of the peptide for research purposes. In its lyophilized state, FOXO4-DRI should be stored at -20 °C (-4 °F) to prevent degradation. Once reconstituted, the peptide must be kept at a temperature range of 2-8 °C (35.6-46.4 °F). Under these conditions, the reconstituted peptide is stable for a maximum of 14 days. Researchers must ensure that storage protocols are meticulously followed to minimize the risk of loss of potency or efficacy, as improper handling could compromise experimental outcomes. It is advisable to monitor storage conditions regularly and to adhere to best practices for peptide storage to ensure reliable results in studies utilizing FOXO4-DRI.

Currently, there is a notable absence of safety data pertaining to human subjects for FOXO4-DRI. Preclinical studies in mice have indicated that administration of 5 mg/kg via intraperitoneal injection led to transient weight loss and reduced food intake, highlighting potential physiological effects that warrant careful consideration. As such, the safety profile remains largely undefined in the context of human research. Furthermore, contraindications have not been established due to the lack of human data; however, caution may be warranted in populations such as pregnant or breastfeeding individuals, as well as those engaged in active wound healing, given the role of senescent cells in tissue repair. Researchers should approach the use of FOXO4-DRI with an awareness of these limitations and the necessity for further investigation into its safety and efficacy.